Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114111 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
A Early Phase 1 study of Seborrheic Dermatitis, sponsored by University of California, Davis.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03114111: Completed Early Phase 1 study of Seborrheic Dermatitis, sponsored by University of California, Davis.
NCT03114111 is a Early Phase 1 study of Seborrheic Dermatitis that has completed, run by University of California, Davis. The registered enrollment target is 12 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03114111, a Early Phase 1 study of Seborrheic Dermatitis, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is: 1. To determine the efficacy of photodynamic therapy (PDT) in the treatment of seborrheic dermatitis. 2. To determine how PDT alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. To determine how PDT alters sebum secretion rates in subjects with seborrheic dermatitis before and after treatment. The researchers hypothesize that PDT will be efficacious in the treatment of seborrheic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG aminolevulinic acid (ALA)
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-12-04 |
| Phase | Early Phase 1 |
What the finished NCT03114111 record still lists
NCT03114111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Seborrheic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03114111 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03114111 about?
NCT03114111 is a clinical study titled "Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis". The purpose of this study is: 1. To determine the efficacy of photodynamic therapy (PDT) in the treatment of seborrheic dermatitis. 2. To determine how PDT alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. To determine how PDT alters sebum secretion ra...
What is the current status of trial NCT03114111?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2017-01. Estimated completion is 2019-12-04.
What conditions does trial NCT03114111 study?
This clinical trial studies the following conditions: Seborrheic Dermatitis.
What interventions are being tested in trial NCT03114111?
The interventions under investigation include: Placebo (DRUG), aminolevulinic acid (ALA) (DRUG).
Who is sponsoring clinical trial NCT03114111?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03114111 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03114111's enrollment target sits among peer trials
12 1530th of 2000 higher than 401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia